Zhaohui Bai1,2, Le Wang1,3, Ran Wang1, Meijuan Zou2, Nahum Méndez-Sánchez4, Fernando Gomes Romeiro5, Gang Cheng2, Xingshun Qi6,7. 1. Liver Cirrhosis Study Group, Department of Gastroenterology, General Hospital of Northern Theater Command, Shenyang, Liaoning, China. 2. NMPA Key Laboratory for Research and Evaluation of Drug Regulatory Technology, Shenyang Pharmaceutical University, Shenyang, Liaoning, China. 3. Postgraduate College, China Medical University, Shenyang, Liaoning, China. 4. Medica Sur Clinic and Foundation and Faculty of Medicine, National Autonomous University of Mexico, Mexico City, Mexico. 5. Botucatu Medical School, São Paulo State University (UNESP), São Paulo, Brazil. 6. Liver Cirrhosis Study Group, Department of Gastroenterology, General Hospital of Northern Theater Command, Shenyang, Liaoning, China. xingshunqi@126.com. 7. NMPA Key Laboratory for Research and Evaluation of Drug Regulatory Technology, Shenyang Pharmaceutical University, Shenyang, Liaoning, China. xingshunqi@126.com.
Abstract
BACKGROUND: Human albumin infusion is effective for controlling systemic inflammation, thereby probably managing some liver cirrhosis-related complications, such as spontaneous bacterial peritonitis (SBP), hepatic encephalopathy (HE), and hepatorenal syndrome. However, its clinical benefits remain controversial. METHODS: EMBASE, PubMed, and Cochrane Library databases were searched. Randomized controlled trials (RCTs) regarding use of human albumin infusion in cirrhotic patients were eligible. Mortality and incidence of liver cirrhosis-related complications were pooled. Effect of human albumin infusion on mortality was also evaluated by subgroup analyses primarily according to target population and duration of human albumin infusion treatment. Odds ratios (ORs) with 95% confidence intervals (CIs) were calculated. RESULTS: Forty-two RCTs were finally included. Meta-analysis showed that human albumin infusion could significantly decrease the mortality of cirrhotic patients (OR = 0.81, 95% CI = 0.67-0.98, p = 0.03). Subgroup analyses showed that human albumin infusion could significantly decrease the mortality of cirrhotic patients with SBP (OR = 0.36, 95% CI = 0.20-0.64, p = 0.0005) and HE (OR = 0.43, 95% CI = 0.22-0.85, p = 0.02), but not those with ascites or non-SBP infections or undergoing large-volume paracentesis. Short-term human albumin infusion treatment could significantly decrease short-term mortality (OR = 0.67, 95% CI = 0.50-0.89, p = 0.005), but not long-term mortality. Long-term human albumin infusion treatment could not significantly decrease long-term mortality (OR = 0.72, 95% CI = 0.48-1.08, p = 0.11). In addition, human albumin infusion could significantly decrease the incidence of renal impairment (OR = 0.63, 95% CI = 0.45-0.88, p = 0.007) and ascites (OR = 0.45, 95% CI = 0.25-0.81, p = 0.007), but not infections or gastrointestinal bleeding. CONCLUSIONS: Human albumin infusion may improve the outcomes of cirrhotic patients. However, its indications for different complications and infusion strategy in liver cirrhosis should be further explored.
BACKGROUND: Human albumin infusion is effective for controlling systemic inflammation, thereby probably managing some liver cirrhosis-related complications, such as spontaneous bacterial peritonitis (SBP), hepatic encephalopathy (HE), and hepatorenal syndrome. However, its clinical benefits remain controversial. METHODS: EMBASE, PubMed, and Cochrane Library databases were searched. Randomized controlled trials (RCTs) regarding use of human albumin infusion in cirrhotic patients were eligible. Mortality and incidence of liver cirrhosis-related complications were pooled. Effect of human albumin infusion on mortality was also evaluated by subgroup analyses primarily according to target population and duration of human albumin infusion treatment. Odds ratios (ORs) with 95% confidence intervals (CIs) were calculated. RESULTS: Forty-two RCTs were finally included. Meta-analysis showed that human albumin infusion could significantly decrease the mortality of cirrhotic patients (OR = 0.81, 95% CI = 0.67-0.98, p = 0.03). Subgroup analyses showed that human albumin infusion could significantly decrease the mortality of cirrhotic patients with SBP (OR = 0.36, 95% CI = 0.20-0.64, p = 0.0005) and HE (OR = 0.43, 95% CI = 0.22-0.85, p = 0.02), but not those with ascites or non-SBP infections or undergoing large-volume paracentesis. Short-term human albumin infusion treatment could significantly decrease short-term mortality (OR = 0.67, 95% CI = 0.50-0.89, p = 0.005), but not long-term mortality. Long-term human albumin infusion treatment could not significantly decrease long-term mortality (OR = 0.72, 95% CI = 0.48-1.08, p = 0.11). In addition, human albumin infusion could significantly decrease the incidence of renal impairment (OR = 0.63, 95% CI = 0.45-0.88, p = 0.007) and ascites (OR = 0.45, 95% CI = 0.25-0.81, p = 0.007), but not infections or gastrointestinal bleeding. CONCLUSIONS: Human albumin infusion may improve the outcomes of cirrhotic patients. However, its indications for different complications and infusion strategy in liver cirrhosis should be further explored.
Authors: Joan Clària; Rudolf E Stauber; Minneke J Coenraad; Richard Moreau; Rajiv Jalan; Marco Pavesi; Àlex Amorós; Esther Titos; José Alcaraz-Quiles; Karl Oettl; Manuel Morales-Ruiz; Paolo Angeli; Marco Domenicali; Carlo Alessandria; Alexander Gerbes; Julia Wendon; Frederik Nevens; Jonel Trebicka; Wim Laleman; Faouzi Saliba; Tania M Welzel; Agustin Albillos; Thierry Gustot; Daniel Benten; François Durand; Pere Ginès; Mauro Bernardi; Vicente Arroyo Journal: Hepatology Date: 2016-08-25 Impact factor: 17.425
Authors: Joan Clària; Richard Moreau; François Fenaille; Alex Amorós; Christophe Junot; Henning Gronbaek; Minneke J Coenraad; Alain Pruvost; Aurélie Ghettas; Emeline Chu-Van; Cristina López-Vicario; Karl Oettl; Paolo Caraceni; Carlo Alessandria; Jonel Trebicka; Marco Pavesi; Carme Deulofeu; Agustin Albillos; Thierry Gustot; Tania M Welzel; Javier Fernández; Rudolf E Stauber; Faouzi Saliba; Noémie Butin; Benoit Colsch; Christophe Moreno; François Durand; Frederik Nevens; Rafael Bañares; Daniel Benten; Pere Ginès; Alexander Gerbes; Rajiv Jalan; Paolo Angeli; Mauro Bernardi; Vicente Arroyo Journal: Hepatology Date: 2019-03-19 Impact factor: 17.425
Authors: Alastair J O'Brien; James N Fullerton; Karen A Massey; Grace Auld; Gavin Sewell; Sarah James; Justine Newson; Effie Karra; Alison Winstanley; William Alazawi; Rita Garcia-Martinez; Joan Cordoba; Anna Nicolaou; Derek W Gilroy Journal: Nat Med Date: 2014-04-13 Impact factor: 53.440